Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Operating Margin
Guardant Health Inc

-75.4%
Current
-103%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-75.4%
=
Operating Profit
-522.1m
/
Revenue
692.3m

Operating Margin Across Competitors

Country US
Market Cap 4.3B USD
Operating Margin
-75%
Country US
Market Cap 94.1B USD
Operating Margin
4%
Country US
Market Cap 88.8B EUR
Operating Margin
4%
Country US
Market Cap 75.4B USD
Operating Margin
3%
Country DE
Market Cap 24.9B EUR
Operating Margin
7%
Country US
Market Cap 20.2B USD
Operating Margin
9%
Country DE
Market Cap 18.7B EUR
Operating Margin
7%
Country US
Market Cap 18.3B USD
Operating Margin
14%
Country US
Market Cap 13.7B USD
Operating Margin
15%
Country DE
Market Cap 12.5B EUR
Operating Margin
7%
Country AU
Market Cap 13.7B AUD
Operating Margin
9%
No Stocks Found

Guardant Health Inc
Glance View

Market Cap
4.3B USD
Industry
Health Care

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

GH Intrinsic Value
34.89 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-75.4%
=
Operating Profit
-522.1m
/
Revenue
692.3m
What is the Operating Margin of Guardant Health Inc?

Based on Guardant Health Inc's most recent financial statements, the company has Operating Margin of -75.4%.